Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab Tiago Torres Current Opinion 02 August 2017 Pages: 1493 - 1503
Drugs in Clinical Development for Fungal Infections Maria F. Gonzalez-LaraJose Sifuentes-OsornioLuis Ostrosky-Zeichner Leading Article 24 August 2017 Pages: 1505 - 1518
Pharmacotherapy of Anal Cancer Jane E. RogersCathy Eng Therapy in Practice 02 August 2017 Pages: 1519 - 1530
Current and Emerging Options for the Management of Inherited von Willebrand Disease Jessica M. HeijdraMarjon H. CnossenFrank W. G. Leebeek Review Article Open access 08 August 2017 Pages: 1531 - 1547
Pharmacotherapy of Myelofibrosis Douglas TremblayBridget MarcellinoJohn Mascarenhas Review Article 08 August 2017 Pages: 1549 - 1563
Abiraterone Acetate: A Review in Metastatic Castration-Resistant Prostrate Cancer Lesley J. Scott Adis Drug Evaluation 17 August 2017 Pages: 1565 - 1576
Canagliflozin: A Review in Type 2 Diabetes Emma D. DeeksAndré J. Scheen Adis Drug Evaluation 23 August 2017 Pages: 1577 - 1592
Fampridine Prolonged Release: A Review in Multiple Sclerosis Patients with Walking Disability Esther S. Kim Adis Drug Evaluation 01 September 2017 Pages: 1593 - 1602
Inotuzumab Ozogamicin: First Global Approval Yvette N. Lamb AdisInsight Report 17 August 2017 Pages: 1603 - 1610
Erratum to: A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs? Wendy L. St. PeterLori D. WaznyJoanna Q. Hudson Erratum 07 August 2017 Pages: 1611 - 1611